

brief report

# Low urinary selenium concentration is associated with nonthyroidal illness syndrome in hospitalized patients with COVID-19

Sara Moreira Anuniação<sup>1,2</sup>  
https://orcid.org/0000-0002-8080-4900

Renata de Oliveira Campos<sup>1,2,3</sup>  
https://orcid.org/0000-0002-2888-4798

Fabyan Esberard de Lima Beltrão<sup>4,5,6</sup>  
https://orcid.org/0000-0001-9713-2584

Déborah Araújo Morais<sup>7</sup>  
https://orcid.org/0000-0003-2390-956X

Wellington Tavares de Sousa Júnior<sup>7</sup>  
https://orcid.org/0000-0001-8901-3219

Fernando Barbosa Júnior<sup>7</sup>  
https://orcid.org/0000-0002-2501-958X

Jéssica Fernanda Cassemiro<sup>1</sup>  
https://orcid.org/0000-0002-3119-769X

Pedro Resende Ferreira Rende<sup>1</sup>  
https://orcid.org/0000-0001-8999-8871

Fabio Hecht<sup>8</sup>  
https://orcid.org/0000-0001-9110-2587

Helton Estrela Ramos<sup>1,2,9</sup>  
https://orcid.org/0000-0002-2900-2099

<sup>1</sup> Departamento de Biorregulação, Instituto de Saúde e Ciências, Universidade Federal da Bahia, Salvador, BA, Brasil

<sup>2</sup> Programa de Pós-graduação em Processos Interativos de Órgãos e Sistemas, Instituto de Ciências e Saúde, Universidade Federal da Bahia, Salvador, BA, Brasil

<sup>3</sup> Centro de Ciências e Saúde, Recôncavo da Universidade Federal da Bahia, Santo Antonio de Jesus, BA, Brasil

<sup>4</sup> Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, PB, Brasil

<sup>5</sup> Programa de Pós-graduação em Ciências da Nutrição, Departamento de Nutrição, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, PB, Brasil

<sup>6</sup> Faculdade de Ciências Médicas, Departamento de Medicina, João Pessoa, PB, Brasil

<sup>7</sup> Departamento de Análises Clínicas, Toxicologia e Ciências dos Alimentos, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil

<sup>8</sup> Department of Biomedical Genetics, University of Rochester, NY, USA

<sup>9</sup> Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brasil

## ABSTRACT

**Objective:** This study aimed to assess urinary selenium concentration (USC) and its correlation with non-thyroidal illness syndrome (NTIS) and inflammatory markers in hospitalized adult patients with COVID-19. **Subjects and methods:** A prospective study was conducted to investigate urinary selenium (Se) concentration in adult patients hospitalized with COVID-19 between June and August 2020. Urine and serum samples were collected before complications occurred, always within the first 48 hours after onset. A total of 121 patients were stratified into three tertiles based on USC: (i) USC < 25 µg/L (40), (ii) USC 25-39 µg/L (41), and (iii) USC > 39 µg/L (40). ICP-MS was employed to measure urinary Se concentration. NTIS was defined by free triiodothyronine below 2.3 pg/L accompanied by low or normal thyroid-stimulating hormone levels. **Results:** NTIS was observed in a low prevalence (5.7%) and was significantly associated with patients having the lowest USC (n = 6, p = 0.008). Thyroiditis was the most prevalent thyroid complication (23.9%); however, there was no significant association with USC (p > 0.05). **Conclusion:** The association between low USC and NTIS was evident in this cohort.

**Keywords:** Selenium; COVID-19; thyroid, nonthyroidal illness syndrome

## INTRODUCTION

Selenium (Se) is an essential trace element for the formation of selenoenzymes, crucial for the proper functioning of the immune, antioxidant, reproductive, and thyroid hormone systems (1). Enzymes such as glutathione peroxidases (GPx), thioredoxin reductases (TRx), and iodothyronine deiodinases play vital

roles in cellular redox control and thyroid hormone biosynthesis (2).

Individuals deficient in Se are more susceptible to impaired immune function, thyroid autoimmune disease, cognitive decline, and increased viral virulence, among other conditions (3). Since the optimal Se level depends on various factors, the literature suggests that an adequate serum Se level ranges between 90-120 µg/L, while the recommended daily intake of this micronutrient should be between 40-400 µg/day (4,5).

In the context of COVID-19, Se deficiency has been linked to increased oxidative damage caused by the SARS-CoV-2 virus, leading to a higher risk of severe disease and mortality (6-10). The elevated levels of reactive oxygen species in patients with COVID-19,

Received on Mar/13/2024  
Accepted on Feb/12/2025

DOI: 10.20945/2359-4292-2024-0113

### Correspondence to:

Helton Estrela Ramos  
Departamento de Biorregulação,  
Instituto de Saúde e Ciências,  
Universidade Federal da Bahia  
Av. Reitor Miguel Calmon, s/n, Vale do Canela  
40110-902 – Salvador, Bahia, BA, Brasil  
ramos.helton@ufba.br.



This is an open-access article distributed under the terms of the Creative Commons Attribution License

coupled with lower levels of the selenoproteins GPxs and TRx, contribute to increased virulence (10,11). Furthermore, scientific findings have shown that low Se levels are associated with altered T cell differentiation, macrophage function, and synthesis of interferon-gamma and tumor necrosis factor-alpha (11,12).

Studies have shown a bidirectional relationship between COVID-19 and the occurrence of thyroid disorders such as thyroiditis, hypothyroidism, and an increased prevalence of NTIS (13-15). NTIS, frequently observed in critical illnesses, is characterized by changes in thyroid hormone (TH) metabolism unrelated to functional abnormalities in the hypothalamic-pituitary-thyroid axis (16). Noteworthy hormonal changes in this condition include reduced triiodothyronine (T3), increased reverse triiodothyronine (rT3), normal or slightly decreased thyroid stimulating hormone (TSH), and elevated concentrations of interleukin 6 (IL-6) (17). Elevated inflammatory cytokines, associated with COVID-19 and NTIS (14,15,18), suggest that Se deficiency may contribute to the onset of NTIS through its antioxidant properties and role in thyroid hormone regulation (1).

The potential risk of Se as a factor for diabetes, insulin resistance, hypertension, and other COVID-19 comorbidities has been explored for several years within the scientific community, yielding differing opinions. However, limited studies have examined the association between Se and NTIS in hospitalized patients with COVID-19. Our previous research focused on clinical, hormonal, and genetic aspects related to COVID-19 mortality in Brazil (19). Nonetheless, the nutritional status of Se in our population has remained poorly understood. Therefore, this study aims to investigate the nutritional status of Se and its association with NTIS in non-critical hospitalized patients with COVID-19.

## SUBJECTS AND METHODS

### Subjects and data collection

This cross-sectional study was aligned with another prospective, observational, analytical study conducted between June and August 2020. A total of 121 consecutive patients with confirmed COVID-19 were recruited from Hospital Metropolitano Dom José Maria Pires, a tertiary referral hospital in João Pessoa,

Paraíba, Brazil. Written consent was obtained from the patients' legal representatives, and the study received approval from the Ethics Committee in Research with Human Beings of the University Hospital Lauro Wanderley (CAAE no. 43097115.2.0000.5188). The study was conducted in accordance with the Declaration of Helsinki and complied with local and national regulations.

All patients tested positive for SARS-CoV-2 using real-time quantitative reverse transcriptase-polymerase chain reaction (Biomol OneStep/COVID-19, IBMP, Paraná, Brazil) with respiratory tract samples (20). Detailed information regarding patient selection has been previously published (19).

### Procedures

Patients over 18 years of age with COVID-19 who were admitted to the hospital's nursing units were included in this research. Blood and urine samples were collected within the first 48 hours of hospitalization, before administering any interventions or therapies that could potentially interfere with or alter the results of Se, TH, or cytokine serum levels.

### Urinary selenium concentrations

Standard operational procedures were followed for collecting, storing, and transporting urine samples. The University of São Paulo's Laboratory of Toxicology and Essentiality of Metals in Ribeirão Preto, Brazil, performed the USC measurements using inductively coupled plasma mass spectrometry (ICP-MS) (PerkinElmer, NexION® 2000, Waltham, USA).

For the USC analysis, a 1:20 dilution was prepared in 0.5% nitric acid and 0.005% Triton. An analytical curve was constructed using the multielement standard solution (PerkinElmer), with concentrations ranging from 0.5 to 100 ppb and base urine for matrix-matched calibration curves. Selenium was the monitored isotope, and all materials used were previously decontaminated with 10% nitric acid for 24 hours (21).

The principle of the analytical technique, ICP-MS, involves using a plasma source energized through electrical currents generated by electromagnetic induction achieved by varying magnetic fields over time. This technique enables multielement analysis of

traces, typically at parts per trillion levels (21). Notably, ICP-MS possesses a high detection capacity, capable of detecting 20-30 metals within minutes, even at significantly low concentrations. Specifically for Se, the urinary detection limit is 0.104 µg/L (22). Analyses were performed in triplicate, and the results were expressed in µg/L.

Given the absence of a universal classification for USC in hospitalized patients, this study considered the reference values for a healthy adult population (10-110 µg/L) (23).

### Serum biochemistry and NTIS diagnosis

C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), and IL-6 were measured using a chemiluminescence immunoassay (Maglumi-2000-Plus, Shenzhen New Industries Biomedical Engineering Co., Shenzhen, China) in accordance with the manufacturer's protocol. According to the 2013 consensus of the Brazilian Society of Endocrinology and Metabolism, hypothyroidism is characterized by a TSH level above 5 µUI/mL and free thyroxine (fT<sub>4</sub>) below 0.89 ng/dL, hyperthyroidism by TSH below 0.4 µUI/mL and fT<sub>4</sub> above 1.72 ng/dL, and NTIS by a serum free triiodothyronine (fT<sub>3</sub>) below 2.3 pg/L, accompanied by low or normal TSH levels (24).

### Statistical analysis

The data, including levels of IL-6, LDH, CRP, D-dimer, age, and body mass index (BMI), were expressed as the median ± interquartile range. Statistical comparisons between different Se tertiles and other groups were conducted using the Mann-Whitney test for continuous variables and the Cochran-Armitage test for categorical variables. The Kruskal-Wallis test was applied to compare all biochemical variables across the tertiles.

Given the lack of reference parameters for urinary Se in individuals with health conditions, the population sample was divided into tertiles. The p-value was employed to reject the null hypothesis and to ascertain the likelihood of differences between groups or variables.

## RESULTS

The mean total USC was 33.8 (standard deviation = 18.8 µg/L) with a median of 31.0 µg/L. Among the

patients studied, 114 (94.2%) had USC levels within the normal range for healthy individuals (10-110 µg/L). The minimum USC observed was 5 µg/L, while the maximum reached 142.9 µg/L. Only seven patients exhibited USC levels below 10 µg/L, representing 5.8% of the study population. **Table 1** demonstrates the association between urinary Se concentration and sociodemographic as well as clinical variables in the study population. The 121 patients were categorized into three groups based on USC tertiles: (i) USC < 25 µg/L (n = 40), (ii) 25 < USC < 39 µg/L (n = 41), and (iii) USC > 39 µg/L (n = 40) (**Table 1**). A significant number of patients in the lowest USC tertile were elderly (n = 22; 55%) (*p* < 0.05). With respect to BMI, a majority of obese individuals were found in the highest USC tertile (n = 28; 78.6%) (*p* < 0.05).

Thyroiditis emerged as the most prevalent thyroid complication, accounting for 23.9% of the cases, yet it did not show a significant association with USC levels (*p* > 0.05). Conversely, NTIS, despite its relatively low prevalence (5.75%), was associated with lower USC levels (*p* < 0.05) (**Table 1**).

## DISCUSSION

Previous findings within this cohort have demonstrated a clear association between serum thyroid hormone levels, inflammatory response, disease severity, and lethality (19,25). However, existing data directly correlating the interplay between Se, COVID-19, and NTIS are limited, underscoring the novelty and importance of the present study in elucidating this relationship.

COVID-19 is characterized by a heightened inflammatory state due to dysregulated cytokine production (26). This elevation in inflammatory cytokines overwhelms the immune system, leading to complications such as multiple organ dysfunctions, increased mortality risk, and organic sequelae (27). Numerous studies have corroborated the inflammatory profile of COVID-19, with serum levels of pro-inflammatory biomarkers, including LDH, CRP, D-dimer, and IL-6, being significantly elevated upon admission in both critical and non-critical patients across multiple clinical trials (28-30).

Excessive cytokine production may contribute to the development of NTIS in the studied population,

**Table 1.** Demographic and clinical characteristics of the patient cohort and their association with thyroid complications and urinary selenium concentration

Variables	Mann-Whitney and Cochran-Armitage tests				
	Total (n = 121)	USC < 25 (n = 40)	25 < USC < 39 (n = 41)	USC > 39 (n = 40)	P
Median age (IQR)	62 (48-75)	66 (55-77)	57 (48-76.5)	56.5 (45-67)	<b>0.047*</b>
BMI (kg/m <sup>2</sup> )	30.5 (27-34)	29.7 (27-32)	29.1 (24-32)	32.6 (29-39)	<b>0.001*</b>
Age > 60 years (%)	52 (42.9)	22 (55)	17 (41.4)	13 (32.5)	<b>0.004*</b>
Male (%)	75 (61.9)	25 (62.5)	27 (65.8)	23 (57.5)	0.212
<b>Thyroid complications</b>					
NTIS (%)	7 (5.7)	6 (15)	1 (2.4)	0 (0)	<b>0.008*</b>
Thyroiditis (%)	29 (23.9)	9 (22.5)	12 (29.2)	8 (20)	0.06

The Mann-Whitney test was utilized for continuous variables, whereas the Cochran-Armitage test was applied to all other variables. BMI: body mass index; IQR: interquartile range; NTIS: non-thyroidal illness syndrome; USC: urinary selenium concentration. \**p* < 0.05 statistically significant.

as pro-inflammatory proteins are associated with its occurrence in critically ill hospitalized patients (29,31,32). It is pertinent to note that Se deficiency is associated with the occurrence and progression of viral and bacterial infections, including human immunodeficiency virus, poliovirus, and tuberculosis (11). Thus, the study population is estimated to be susceptible to the same scenario.

The heightened inflammatory state indicates intense defense system activation, potentially affecting Se availability and depleting its reserves. The hyper-responsiveness to inflammation and immunological demand in COVID-19 underscores the importance of antioxidants and modulators in inflammation control, highlighting Se's critical role at this stage (18). Adequate Se levels in this population could beneficially impact the balance between self-reactive disease activity and thyroid function, given Se's essential contributions to this system (33). Hence, it is suggested that lower USC favored the imbalance between the reduction in amount or activity of thyroid selenoproteins, such as glutathione peroxidase type 3 and selenoprotein S, and the pronounced inflammatory state in the population (29,31,32).

Several studies have demonstrated the correlation between pro-inflammatory cytokines, specifically interleukin 1 $\beta$ , IL-6, and tumor necrosis factor-alpha, and the onset of metabolic alterations in TH and NTIS. In the context of critical conditions and highly inflammatory diseases such as COVID-19, there is an alteration in the metabolism of TH through the induction of iodothyronine deiodinase 3, a Se-dependent enzyme

(34-36). This alteration leads to an increase in T<sub>3</sub> clearance and rT<sub>3</sub> production. Additionally, critical illness also results in a decreased expression of iodothyronine deiodinase 1 (D1) in the liver, consequently reducing the production and clearance of T<sub>3</sub>r (36). This phenomenon appears to be linked with increased free radical generation in tissues, which can decrease activity due to oxidative damage to this enzyme (37). Furthermore, elevated circulating glucocorticoids, a drug class recommended in severe COVID-19 cases, may also diminish D1 activity (38).

In an *in vitro* study, sodium selenite was shown to partially counteract the oxidative stress generated by high concentrations of IL-6 induced in a cellular model simulating NTIS, thereby providing evidence of Se's role in modulating the disease's underlying mechanisms (39). Another randomized controlled trial involving 68 dialysis patients who received high-dose Se supplementation (200  $\mu$ g/day for 12 weeks) demonstrated a reduction in rT<sub>3</sub> levels (40). These studies, along with the findings from the present cohort, underscore the significant contribution of Se to thyroid health, particularly in patients with COVID-19 (2).

In our cohort, we previously reported a statistically significant association between serum fT<sub>3</sub> (a marker of NTIS), CRP, neutrophil count, serum IL-6, albumin, and the D-dimer ratio with mortality (25). Additionally, in assessing the influence of BMI on the USC of our cohort, we found that patients with higher USC exhibited a greater BMI, which was significantly associated when patients were stratified into USC tertiles. This observation requires further confirmation in future

studies, especially due to the altered micronutrient intake prior to hospital admission caused by the severity of the disease.

USC offered more feasibility in our study, given that 50%-70% of dietary Se is excreted through urine, and a single urine collection is practical and less invasive. It has been utilized in epidemiological studies such as the National Health and Nutrition Examination Survey III and the Canadian Health Measures Survey, as well as in biomonitoring studies assessing metal exposure. Conversely, serum Se assessment is invasive, requires trained professionals for analysis, and is more time-consuming (41,43).

Some limitations of the current study include the non-association of Se status with certain data, such as the method's specificity for a highly specific population, the lack of urinary Se reference parameters in ill individuals, and the potential interference from confounding factors. Including plasma markers, such as serum Se or plasma selenoprotein P could have mitigated the study's multiple biases. Although we did not evaluate the activity of Se-dependent enzymes, it is established that GPx is essential for protecting the thyroid gland from oxidative damage and for regulating the availability of Se for selenoprotein synthesis, including deiodinases.

In the context of NTIS associated with COVID-19, a decrease in GPx activity due to Se deficiency, could correlate with diminished deiodinase activity and altered thyroid hormone metabolism, contributing to oxidative stress and impaired conversion of  $T_4$  to the active form  $T_3$ . The reduction in these enzymes may further exacerbate the hormonal imbalance observed in hypothyroidism (44,45). However, practical challenges such as obtaining adequate blood sample aliquots for storage, transport, and analysis have made urinary samples a more cost-effective and feasible option in this context.

In conclusion, nonthyroidal illness syndrome emerged as the most significant complication in this study and was associated with low levels of urinary selenium in the affected population, likely due to elevated pro-inflammatory markers. This finding supports the importance of evaluating the selenium nutritional profile and its potential protective effects in hospitalized patients with COVID-19.

**Funding:** the authors declare that no funding, subsidy, or other support was received during the preparation of this manuscript.

**Author contributions:** all authors contributed to the conception and design of this study. Material preparation, data collection and analysis were performed by Sara Moreira Anuniação, Renata de Oliveira Campos, Fabyan Esberard de Lima Beltrão, Déborah Araújo Morais, Wellington Tavares de Sousa Júnior, Fernando Barbosa Júnior, Fábio Hecht Castro Medeiros, Jéssica Fernanda Cassemiro, Pedro Resende Ferreira Rende and Helton Estrela Ramos. The first draft of the manuscript was written by Sara Moreira Anuniação and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Data availability:** the datasets generated and/or analyzed during the present study are available in the Institutional Repository of the Federal University of Paraíba at the link <https://repositorio.ufpb.br/jspui/simplesearch?query=AVALIA%C3%87%C3%83O+DA+FUN%C3%87%C3%83O+TIREOIDIANA+E+POLIMORFISMO+THR92ALA-D2+DO+GENE+DA+DESIODASE+TIPO+2+COMO+BIOMARCADORES+D-E+MORTALIDADE+NA+COVID-19++>

**Ethics approval:** this study was conducted in adherence to the principles outlined in the Declaration of Helsinki. The work was submitted and approved by the Ethics and Research Committee of the Health Sciences Center in accordance with Resolution no. 466 of the National Health Council on May 12, 2020 (opinion no. 4,024,145; CAAE no. 43097115.2.0000.5188). All participants over 18 or older signed an informed consent form.

**Consent to participate:** informed consent was obtained from all participants in the study.

**Acknowledgments:** we gratefully acknowledge the contributions and efforts of all patients who participated in this study, as well as the physicians, residents, students, nutritionists, pharmacists, and healthcare professionals involved in data collection and patient care. We also extend our thanks to the hospital management of Dom José Maria Pires Metropolitan Hospital, the Teaching and Research Management of Lauro Wanderley University Hospital, and the University Center of João Pessoa (UNIPE).

**Disclosure:** no potential conflict of interest relevant to this article was reported.

## REFERENCES

1. Avery J, Hoffmann P. Selenium, Selenoproteins, and Immunity. *Nutrients*. 2018 Sep 1;10(9):1203. doi: 10.3390/nu10091203.
2. Silvestrini A, Mordente A, Martino G, Bruno C, Vergani E, Meucci E, et al. The Role of Selenium in Oxidative Stress and in Nonthyroidal Illness Syndrome (NTIS): An Overview. *Curr Med Chem*. 2020;27(3):423-49. doi: 10.2174/0929867325666180201111159.
3. Rayman MP. Selenium intake, status, and health: a complex relationship. *Hormones (Athens)*. 2020 Mar;19(1):9-14. doi: 10.1007/s42000-019-00125-5.
4. Kipp AP, Strohm D, Brigelius-Flohé R, Schomburg L, Bechthold A, Leschik-Bonnet E, et al. Revised reference values for selenium intake. *J Trace Elem Med Biol*. 2015 Oct;32:195-9. doi: 10.1016/j.jtemb.2015.07.005.
5. Gorini F, Sabatino L, Pingitore A, Vassalle C. Selenium: An Element of Life Essential for Thyroid Function. *Molecules*. 2021 Nov 23;26(23):7084. doi: 10.3390/molecules26237084.

6. Moghaddam A, Heller R, Sun Q, Seelig J, Cherkezov A, Seibert L, et al. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. *Nutrients*. 2020 Jul 16;12(7):2098. doi: 10.3390/nu12072098.
7. Majeed M, Nagabhushanam K, Gowda S, Mundkur L. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status. *Nutrition*. 2021 Feb;82:111053. doi: 10.1016/j.nut.2020.111053.
8. Younesian O, Khodabakhshi B, Abdolahi N, Norouzi A, Behnampour N, Hosseinzadeh S, et al. Decreased Serum Selenium Levels of COVID-19 Patients in Comparison with Healthy Individuals. *Biol Trace Elem Res*. 2022 Apr;200(4):1562-7. doi: 10.1007/s12011-021-02797-w.
9. Im JH, Je YS, Baek J, Chung M-H, Kwon HY, Lee J-S. Nutritional status of patients with COVID-19. *Int J Infect Dis*. 2020 Nov;100:390-3. doi: 10.1016/j.ijid.2020.08.018.
10. Skesters A, Kustovs D, Lece A, Moreino E, Petrosina E, Rainsford KD. Selenium, selenoprotein P, and oxidative stress levels in SARS-CoV-2 patients during illness and recovery. *Inflammopharmacology*. 2022 Apr;30(2):499-503. doi: 10.1007/s10787-022-00925-z.
11. Martinez SS, Huang Y, Acuna L, Laverde E, Trujillo D, Barbieri MA, et al. Role of Selenium in Viral Infections with a Major Focus on SARS-CoV-2. *Int J Mol Sci*. 2021 Dec 28;23(1):280. doi: 10.3390/ijms23010280.
12. Alexander J, Tinkov A, Strand TA, Alehagen U, Skalny A, Aaseth J. Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19. *Nutrients*. 2020 Aug 7;12(8):2358. doi: 10.3390/nu12082358.
13. Duntas LH, Jonklaas J. COVID-19 and Thyroid Diseases: A Bidirectional Impact. *J Endocr Soc*. 2021 Apr 27;5(8):bvab076. doi: 10.1210/jendso/bvab076.
14. Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. *J Endocrinol Invest*. 2021 Sep;44(9):1801-14. doi: 10.1007/s40618-021-01554-z.
15. Somasundaram NP, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Dissanayake HA, Yogendranathan N, et al. The Impact of SARS-Cov-2 Virus Infection on the Endocrine System. *J Endocr Soc*. 2020 Jul 2;4(8):bvaa082. doi: 10.1210/jendso/bvaa082.
16. Vidart J, Jaskulski P, Kunzler AL, Marschner RA, Ferreira de Azeredo da Silva A, Wajner SM. Non-thyroidal illness syndrome predicts outcome in adult critically ill patients: a systematic review and meta-analysis. *Endocr Connect*. 2022 Feb 9;11(2):e210504. doi: 10.1530/EC-21-0504.
17. Van den Berghe G. Non-Thyroidal Illness in the ICU: A Syndrome with Different Faces. *Thyroid*. 2014 Oct;24(10):1456-65. doi: 10.1089/thy.2014.0201.
18. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. *Rev Endocr Metab Disord*. 2021 Dec;22(4):803-15. doi: 10.1007/s11154-020-09615-z.
19. de Lima Beltrão FE, de Almeida Beltrão DC, Carvalho G, de Lima Beltrão FE, de Souza Braga Filho J, de Brito Oliveira J, et al. Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intra-hospital Mortality of COVID-19. *J Clin Endocrinol Metab*. 2022 May 17;107(6):e2488-e2501. doi: 10.1210/clinem/dgac075.
20. Ministério da Saúde. Protocolo de Manejo Clínico da Covid-19 na Atenção Especializada [Internet]. 1ª ed. Brasília: Ministério da Saúde; 2020 [cited 2022 Aug 19]. Available from: [https://bvsms.saude.gov.br/bvs/publicacoes/manejo\\_clinico\\_covid-19\\_atencao\\_especializada.pdf](https://bvsms.saude.gov.br/bvs/publicacoes/manejo_clinico_covid-19_atencao_especializada.pdf)
21. Pröfrock D, Prange A. Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) for Quantitative Analysis in Environmental and Life Sciences: A Review of Challenges, Solutions, and Trends. *Appl Spectrosc*. 2012 Aug;66(8):843-68. doi: 10.1366/12-06681.
22. Pruszkowski E, Neubauer K. The Analysis of Urine for Trace Elements using the NexION 2000 ICP-MS [Internet]. Waltham; 2017. Available from: [https://resources.perkinelmer.com/lab-solutions/resources/docs/app-nexion-2000-icp-ms-trace-elements-in-urine-013256a\\_01.pdf](https://resources.perkinelmer.com/lab-solutions/resources/docs/app-nexion-2000-icp-ms-trace-elements-in-urine-013256a_01.pdf)
23. Hays SM, Macey K, Nong A, Aylward LL. Biomonitoring Equivalents for selenium. *Regul Toxicol Pharmacol*. 2014 Oct;70(1):333-9. doi: 10.1016/j.yrtph.2014.07.017.
24. Carvalho GA de, Perez CLS, Ward LS. Utilização dos testes de função tireoidiana na prática clínica. *Arq Bras Endocr Metab*. 2013;57:193-204. doi: 10.1590/S0004-27302013000300005
25. Beltrão FE de L, Beltrão DC de A, Carvalho G, Beltrão FE de L, Brito A da S, Capistrano KHR da, et al. Thyroid Hormone Levels During Hospital Admission Inform Disease Severity and Mortality in COVID-19 Patients. *Thyroid*. 31(11):1639-49. doi: 10.1089/thy.2021.0225.
26. Muzembo BA, Mbendi NC, Ngatu NR, Suzuki T, Wada K, Ikeda S. Serum selenium levels in tuberculosis patients: A systematic review and meta-analysis. *J Trace Elem Med Biol*. 2018 Dec;50:257-62. doi: 10.1016/j.jtemb.2018.07.008.
27. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine Growth Factor Rev*. 2020 Jun;53:25-32. doi: 10.1016/j.cytogfr.2020.05.003.
28. Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. *Zhonghua Jie He Chivito Hu Xi Za Zhi*. 2020;43.
29. Chu H, Chan JF, Wang Y, Yuen TT, Chai Y, Hou Y, et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study with Implications for the Pathogenesis of COVID-19. *Clin Infect Dis*. 2020 Sep 12;71(6):1400-9. doi: 10.1093/cid/ciaa410.
30. Cecchini R, Cecchini AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. *Med Hypotheses*. 2020 Oct;143:110102. doi: 10.1016/j.mehy.2020.110102.
31. Speer G, Somogyi P. Thyroid complications of SARS and coronavirus disease 2019 (COVID-19). *Endocr J*. 2021 Feb 28;68(2):129-36. doi: 10.1507/endocr.EJ20-0443.
32. Hu S, Rayman MP. Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. *Thyroid*. 2017 May;27(5):597-610. doi: 10.1089/thy.2016.0635.
33. Koekkoek WAC (Kristine), van Zanten ARH. Antioxidant Vitamins and Trace Elements in Critical Illness. *Nutr Clin Pract*. 2016 Aug;31(4):457-74. doi: 10.1177/0884533616653832.
34. Pirola I, Gandossi E, Agosti B, Delbarba A, Cappelli C. Selenium supplementation could restore euthyroidism in subclinical hypothyroid patients with autoimmune thyroiditis. *Endokrynol Pol*. 2016;67(6):567-71. doi: 10.5603/EP.2016.0064.
35. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. *Lancet Diabetes Endocrinol*. 2015 Oct;3(10):816-25. doi: 10.1016/S2213-8587(15)00225-9.
36. Peeters RP, van der Geyten S, Wouters PJ, Darras VM, van Toor H, Kaptein E, et al. Tissue Thyroid Hormone Levels in Critical Illness. *J Clin Endocrinol Metab*. 2005 Dec;90(12):6498-507. doi: 10.1210/jc.2005-1013.
37. Huang TS, Boado RJ, Chopra IJ, Solomon DH, Teco GN. The effect of free radicals on hepatic 5'-monodeiodination of thyroxine and 3,3',5'-triiodothyronine. *Endocrinology*. 1987 Aug;121(2):498-503. doi: 10.1210/endo-121-2-498.
38. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3',5'-triiodothyronine (T3). *J Clin Endocrinol Metab*. 1975 Nov;41(5):911-20. doi: 10.1210/jcem-41-5-911.
39. Wajner SM, Rohenkohl HC, Serrano T, Maia AL. Sodium selenite supplementation does not fully restore oxidative stress-induced deiodinase dysfunction: Implications for the nonthyroidal illness syndrome. *Redox Biol*. 2015 Dec;6:436-45. doi: 10.1016/j.redox.2015.09.002.
40. Shahreki E, Kaykhaei MA, Mosallanezhad Z, Adineh Z, Mokhtari AM, Mohammadi M, et al. Effects of Selenium and/or N-Acetyl-Cysteine Supplementation on Nonthyroidal Illness Syndrome in Hemodialysis

Patients: A Factorial Randomized Controlled Trial. *Pharmacology*. 2022;107(9-10):480-5. doi: 10.1159/000525094.

41. Dos Santos M, Veneziani Y, Muccillo-Baisch AL, Da Silva Júnior FMR. Global survey of urinary selenium in children: A systematic review. *J Trace Elem Med Biol*. 2019 Dec;56:1-5. doi: 10.1016/j.jtemb.2019.07.001.
42. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. *Eur J Clin Nutr*. 2004 Mar;58(3):391-402. doi: 10.1038/sj.ejcn.1601800.
43. Hays SM, Macey K, Nong A, Aylward LL. Biomonitoring equivalents for selenium. *Regul Toxicol Pharmacol*. 2014 Oct;70(1):333-9. doi: 10.1016/j.yrtph.2014.07.017.
44. Rua RM, Nogales F, Carreras O, Ojeda ML. Selenium, selenoproteins and cancer of the thyroid. *J Trace Elem Med Biol*. 2023 Mar;76:127115. doi: 10.1016/j.jtemb.2022.127115.
45. Ayyappan S, Dhas P K. Selenium and Selenium-Dependent Enzymes in Hypothyroidism. *Chettinad Health City Med J*. 2024;13(1):87-91. doi: 10.24321/2278.2044.202415